Asia Pacific Biologics Contract Manufacturing Market Insights, 2021-2031

Biologics Contract Manufacturing Market (Type: Monoclonal, Antibodies, Recombinant, Proteins, Vaccines, Molecular Therapy, and Others) - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Rise in Sales of Bioreactors Due to High COVID-19 Vaccine Demand

Since hormones, fusion proteins, and vaccines form an important part of biologics, bioreactor sales are witnessing an upsurge during the COVID-19 outbreak. Such trends are contributing to the growth of the Asia Pacific biologics contract manufacturing market. Bioreactor sales have registered a notable increase during 2020 with many companies expanding their facilities in order to fulfil the demand for COVID-19 vaccine production.

Nationwide vaccination programs are creating revenue opportunities for stakeholders in the Asia Pacific biologics contract manufacturing market. The increasing government focus on encouraging the growth of local biotech companies by offering direct investments, tax incentives, and other resources is growing prominent in countries of Asia Pacific. Since vaccination is an underutilized public health intervention, stakeholders are working closely with governments to deploy initiatives for immunization of populations.

asia pacific biologics contract manufacturing market infographic

Request a sample to get extensive insights into the Biologics Contract Manufacturing Market

Can Process Intensification Tide Over Hurdles in Biologics Contract Manufacturing?

The patient-specific therapy is gaining importance for biopharmaceutical research. Biologics manufacturing challenges can emerge in multiple areas, but leading bio-manufacturers are addressing these difficulties with the help of process intensification (PI). Process intensification refers to a list of comprehensive initiatives that can maximize the efficiency of a bioprocess and make a biologic product more successful.

The perennial problem of productivity is affecting the growth of the Asia Pacific biologics contract manufacturing market. Thus, process intensification holds promising potentials to help introduce new products in a shorter period of time. With greater production capacity, biopharma organizations can scale their processes to meet patient demands.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Optimized Digital Manufacturing Helps Accelerate Product Innovations

The Asia Pacific biologics contract manufacturing market is expected to register a CAGR of 14.5% during the forecast period. In order to overcome challenges in biologics contract manufacturing, optimized digital manufacturing is gaining prominence as an essential remedy to boost productivity levels and adhere to high compliance standards. This strategy is helping biopharma organizations to become more technologically progressive and adaptive than other manufacturers.

Optimized digital manufacturing is helping companies in the Asia Pacific biologics contract manufacturing market to accelerate product innovations and ramp-up projects as per market demand trends. The automation of manufacturing processes is another key driver of the market.

Steep Cost of Biologics Acting as Barrier to Patient Access

The Asia Pacific biologics contract manufacturing market is projected to reach the valuation of US$ 9.8 Bn by 2031. The high prevalence of cancer is catalyzing the demand for biologics. However, the steep cost of these drugs is acting as a barrier to patient access. Nevertheless, patents in several oncology biologics are predicted to expire during the upcoming years, which is creating an opportunity for companies to introduce cost-efficient biosimilars.

Pharmaceutical manufacturers in the Asia Pacific biologics contract manufacturing market are shifting their focus from generics and joining the fray motivated by advantageous global and local regulations. For instance, Celltrion - a biopharmaceutical company headquartered in Incheon, South Korea, is acquiring recognition for successfully gaining regulatory approval in Europe companies with infliximab, a monoclonal antibody.

Strong Intent of Asian Companies to Bring Biosilimars into Western Markets

Even though patients may find the price of biologics to be high, Asia-based companies are at an advantageous position, since a lower cost base relative to countries in Europe and the U.S. is grabbing attention of stakeholders. Companies in the Asia Pacific biologics contract manufacturing market are capitalizing on low capital expenditure for manufacturing facilities, low biosimilar development costs, and cost efficient labor to advance in the healthcare landscape.

In China, a regulatory change permitting pharmaceutical companies to outsource manufacturing to CMOs (Contract Manufacturing Organizations) has led to new opportunities for biotechs to concentrate on innovative drug development. There is a strong intent of companies located in Asia to bring biosilimars into western markets.

asia pacific biologics contract manufacturing market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Biologics Contract Manufacturing Market

Analysts’ Viewpoint

Companies in the Asia Pacific biologics contract manufacturing market are upgrading their infrastructure to accelerate the process development of COVID-19 vaccines. With the help of process intensification, stakeholders are deploying services that boost production whilst reducing the carbon footprint. Although biosimilars offer a similar clinical outcome as their reference counterparts at a reduced price, it is still important for manufacturers to seek recognition in the U.S., which limits its uptake. Nevertheless, biopharma organizations in Asia Pacific should stay flexible and respond to changing demands of patients. Research breakthroughs and new molecule discoveries are contributing to market expansion. The process intensification can help bio-manufacturing efforts become more responsive as technologies evolve rapidly.

Asia Pacific Biologics Contract Manufacturing Market: Overview

  • According to Transparency Market Research’s latest research report on the biologics contract manufacturing market in Asia Pacific for the historical year 2020 and the forecast period from 2021 to 2031, increase in sales of biopharmaceuticals and number of molecules in the pipeline being developed by small and virtual biotech companies are projected to drive the demand for biologics contract manufacturing during the forecast period
  • The biologics contract manufacturing market in Asia Pacific is anticipated to reach US$ 9.8 Bn by 2031, expanding at a CAGR of 14.5% from 2021 to 2031. Rest of Asia Pacific is projected to be a highly attractive market during the forecast period, with attractiveness index of 1.1. The region accounted for 41.7% share of the market in 2020. The sub-region's dominance can be attributed to the presence of China.
  • Based on type, the monoclonal antibodies segment held major market share in 2020. The segment’s dominance can be attributed to increase in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.

Increase in Demand for Biopharmaceutical Contract Manufacturing Services: Key Driver

  • Countries in Asia are emerging as desirable outsourcing destinations for the biopharmaceutical industry. Low manufacturing and operating costs in China and India are the key drivers of the contract manufacturing market in Asia Pacific. Due to low labor wages, pharmaceutical companies in China can reduce their manufacturing costs by 30% to 35%. Moreover, favorable tax incentives and an undervalued currency are likely to drive the market in the region during the forecast period. Growth of the biopharmaceutical industry in China and India is projected to propel the biopharmaceutical contract manufacturing market in Asia Pacific.

Growth of Vaccines Segment: Major Driver

  • The threat of new diseases and pandemics such as COVID-19 has spurred the development of biologic vaccines. Increase in incidence of infectious diseases is projected to drive the vaccines segment during the forecast period.

Asia Pacific Biologics Contract Manufacturing Market: Competition Landscape

  • Detailed profiles of biologics contract manufacturers have been provided in the biologics contract manufacturing market report to evaluate their financials, key product offerings, recent developments, and strategies
  • Key providers of biologics contract manufacturing focus on designing advanced and cost-effective solutions to leading biopharmaceuticals organizations
  • Major companies operating in Asia Pacific biologics contract manufacturing markets are
    • Lonza Group
    • Samsung Biologics Co., Ltd.
    • Patheon by Thermo Fisher Scientific, Inc.
    • Cambrex Corporation
    • Siegfried Holding AG
    • Others

Asia Pacific Biologics Contract Manufacturing Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 2.4 Bn

Market Forecast Value in 2031

US$ 9.8 Bn

Growth Rate (CAGR)

14.5%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, supply chain analysis, and parent industry overview.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Monoclonal
    • Antibodies
    • Recombinant
    • Proteins
    • Vaccines
    • Molecular Therapy
    • Others

Regions Covered

  • Asia Pacific

Countries Covered

  • Japan
  • South Korea
  • Taiwan
  • Singapore
  • Thailand
  • India
  • Rest of Asia Pacific

Companies Covered

  • Lonza Group
  • Samsung Biologics Co., Ltd.
  • Patheon by Thermo Fisher Scientific, Inc.
  • Cambrex Corporation
  • Siegfried Holding AG
  • Fujifilm Holding Corporation
  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Recipharm Pharmaceuticals
  • WuXi Biologics
  • Catalent, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Asia Pacific Biologics Contract Manufacturing Market – Segmentation

TMR’s research study assesses the biologics contract manufacturing market in Asia Pacific based on type and country. The report presents extensive market dynamics and progressive trends associated with different segments and how they influence growth prospects of the biologics contract manufacturing market in Asia Pacific.

Type
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Molecular Therapy
  • Others
Country
  • Japan
  • South Korea
  • Taiwan
  • Singapore
  • Thailand
  • India
  • Rest of Asia Pacific

Frequently Asked Questions

What is the total market worth of asia pacific biologics contract manufacturing market?

Biologics contract manufacturing market in asia pacific is projected to reach the valuation of US$ 9.8 Bn by 2031

What is the anticipated CAGR of the asia pacific biologics contract manufacturing market in the forecast period?

Biologics contract manufacturing market in asia pacific to expand at a CAGR of 14.5% from 2021 to 2031

What are the key driving factors for the growth of the asia pacific biologics contract manufacturing market?

Biologics contract manufacturing market is driven by increase in sales of biopharmaceuticals and number of molecules in the pipeline being developed by small and virtual biotech companies

Which is the rising prominent segment in the asia pacific biologics contract manufacturing market?

The monoclonal antibodies segment dominated the asia pacific biologics contract manufacturing marketand the trend is projected to continue during the forecast period

Who are the key players in the asia pacific biologics contract manufacturing market?

Key players in asia pacific biologics contract manufacturing markets include Lonza Group, Samsung Biologics Co., Ltd., Patheon by Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Others

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global & Asia Pacific Biologics Contract Manufacturing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Biologics Contract Manufacturing: Overview

        5.2. Trends in Biopharma Contract Manufacturing

        5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type, 2017–2031

            6.3.1. Monoclonal Antibodies

            6.3.2. Recombinant Proteins

            6.3.3. Vaccines

            6.3.4. Molecular Therapy

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Type

    7. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Country/Sub-Region

        7.1. Key Findings

        7.2. Market Value Forecast, by Country/Sub-Region

            7.2.1. Japan

            7.2.2. South Korea

            7.2.3. Taiwan

            7.2.4. Singapore

            7.2.5. Thailand

            7.2.6. India

            7.2.7. Rest of Asia Pacific

        7.3. Market Attractiveness Analysis, by Country/Sub-Region

    8. Japan Biologics Contract Manufacturing Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast, by Type, 2017–2031

            8.2.1. Monoclonal Antibodies

            8.2.2. Recombinant Proteins

            8.2.3. Vaccines

            8.2.4. Molecular Therapy

            8.2.5. Others

        8.3. Market Attractiveness Analysis

            8.3.1. By Type

    9. South Korea Biologics Contract Manufacturing Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Type, 2017–2031

            9.2.1. Monoclonal Antibodies

            9.2.2. Recombinant Proteins

            9.2.3. Vaccines

            9.2.4. Molecular Therapy

            9.2.5. Others

        9.3. Market Attractiveness Analysis

            9.3.1. By Type

    10. Taiwan Biologics Contract Manufacturing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Type, 2017–2031

            10.2.1. Monoclonal Antibodies

            10.2.2. Recombinant Proteins

            10.2.3. Vaccines

            10.2.4. Molecular Therapy

            10.2.5. Others

        10.3. Market Attractiveness Analysis

            10.3.1. By Type

    11. Singapore Biologics Contract Manufacturing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017–2031

            11.2.1. Monoclonal Antibodies

            11.2.2. Recombinant Proteins

            11.2.3. Vaccines

            11.2.4. Molecular Therapy

            11.2.5. Others

        11.3. Market Attractiveness Analysis

            11.3.1. By Type

    12. Thailand Biologics Contract Manufacturing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017–2031

            12.2.1. Monoclonal Antibodies

            12.2.2. Recombinant Proteins

            12.2.3. Vaccines

            12.2.4. Molecular Therapy

            12.2.5. Others

        12.3. Market Attractiveness Analysis

            12.3.1. By Type

    13. India Biologics Contract Manufacturing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type, 2017–2031

            13.2.1. Monoclonal Antibodies

            13.2.2. Recombinant Proteins

            13.2.3. Vaccines

            13.2.4. Molecular Therapy

            13.2.5. Others

        13.3. Market Attractiveness Analysis

            13.3.1. By Type

    14. Rest of Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type, 2017–2031

            14.2.1. Monoclonal Antibodies

            14.2.2. Recombinant Proteins

            14.2.3. Vaccines

            14.2.4. Molecular Therapy

            14.2.5. Others

        14.3. Market Attractiveness Analysis

            14.3.1. By Type

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2020

        15.3. Company Profiles

            15.3.1. Lonza Group

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Strategic Overview

                15.3.1.4. SWOT Analysis

            15.3.2. Samsung Biologics Co., Ltd.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Strategic Overview

                15.3.2.4. SWOT Analysis

            15.3.3. Patheon by Thermo Fisher Scientific, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Strategic Overview

                15.3.3.4. SWOT Analysis

            15.3.4. Siegfried Holding AG

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Strategic Overview

                15.3.4.4. SWOT Analysis

            15.3.5. Cambrex Corporation

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Strategic Overview

                15.3.5.4. SWOT Analysis

            15.3.6. Boehringer Ingelheim

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Strategic Overview

                15.3.6.4. SWOT Analysis

            15.3.7. Recipharm Pharmaceuticals

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Strategic Overview

                15.3.7.4. SWOT Analysis

            15.3.8. Catalent Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Strategic Overview

                15.3.8.4. SWOT Analysis

            15.3.9. WuXi Biologics

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Strategic Overview

                15.3.9.4. SWOT Analysis

            15.3.10. Fujifilm Holding Corporation

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Strategic Overview

                15.3.10.4. SWOT Analysis

            15.3.11. AbbVie, Inc.

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Portfolio

                15.3.11.3. Strategic Overview

                15.3.11.4. SWOT Analysis

    List of Tables

    Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 02: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 03: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 04: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 05: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 06: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 07: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 08: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 09: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    List of Figures

    Figure 01: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Type, 2020

    Figure 03: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Country/Sub-Regions, 2020

    Figure 04: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 05: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 06: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031

    Figure 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017‒2031

    Figure 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017‒2031

    Figure 09: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017‒2031

    Figure 10: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017–2031

    Figure 11: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021–2031

    Figure 12: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031

    Figure 13: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 14: Japan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 15: Japan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 16: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 17: South Korea Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 18: South Korea Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 19: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 20: Taiwan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 21: Taiwan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 22: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 23: Singapore Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 24: Singapore Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 25: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 26: Thailand Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 27: Thailand Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 28: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 29: India Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 30: India Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 31: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 32: Rest of Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

    Figure 33: Rest of Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved